Bebtelovimab

BIOLOGICAL2 trials

Sponsors

Eli Lilly and Company, Erin McCreary

Conditions

COVID-19Covid19

Phase 2

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

CompletedNCT04634409

Eli Lilly and CompanyCOVID-19

Start: 2020-10-29End: 2021-10-18Updated: 2022-07-01

Phase 4

UPMC OPTIMISE-C19 Trial, a COVID-19 Study

TerminatedNCT04790786

Erin McCrearyCovid19

Start: 2021-03-10End: 2022-06-16Updated: 2023-06-15

Related Papers

Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19.

2024-09-041 citations

Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.

2024-01-305 citations

Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge

JAMA Network Open2022-07-1452 citations

The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial.

2022-06-1117 citations

A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.

2021-08-1029 citations

The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.

2021-05-2524 citations